Institutional Sign In

Go

GlaxoSmithKline Czech Republic - Total Debt Growth

GlaxoSmithKline CR`s Total Debt Growth reached -100 % in 2014. This is 400 % less than in the previous year.

$1.99

Buy Total Debt Growth data for GlaxoSmithKline Czech Republic.

$19.99

Buy all data for GlaxoSmithKline Czech Republic.

from $199/month

Buy annual subscriptions for all our products.

 
Company Unit 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Amgen Czech Republic % ... ... ... ... ... ... ... ... ... ... ... ... ... 137,021 80.5   ...
Bayer Czech Republic % ... ... ... ... ... ... ... ...   ... ... ... ... -68.3 428    
GlaxoSmithKline Czech Republic % ... ... ...               74.0 -33.7 33.3 -100 ... ... ...
Merck Czech Republic % ... ...                 24.2 -12.8 18.1 -85.0 -100 ... ...
Novartis Czech Republic %         ...           24.4 -73.0 -100 ... -100 ...  
Pfizer Czech Republic % ... ... ... ...       ...   ... ... -100 ... ... ... ... ...
Roche Czech Republic % ... ... ...           ...   -100 ... 88.9 89.9 21.8   ...
Sanofi-Aventis Czech Republic % ... ... ... ...             -7.86 21.0 -37.4 -46.6 -14.2    
Walmark % ... ... ...               -36.1 327 -1.50 7.02 61.0